Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Description
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia. MeSH
Hierarchy View
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (17)
Phase 2 Indicated Drugs (104)
allogeneic cytomegalovirus-specific cytotoxic t lymphocytes
anti-cd19/20-car vector-transduced t cells
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells
cd45-depleted allogenic peripheral blood stem cell
hla-matched related donor bone marrow
in vitro-treated peripheral blood stem cell
Phase 1 Indicated Drugs (89)
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
cd19-cd34 car transduced t cells
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins
Other Experimental Indicated Drugs (12)
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.